Managing Advanced Stages of Friedreich’s Ataxia: Challenges and Emerging Therapeutic Avenues : Episode 2
Opinion
Video
Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy
A key opinion leader examines the November 2022 guidelines for managing Friedreich's ataxia, discusses the first FDA-approved therapy for the condition, and explains how this treatment is integrated into current disease management strategies.
EP: 1.Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities
Now Viewing
EP: 2.Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy
EP: 3.Engaging mFARS Scale to Monitor Friedreich Ataxia Progression
EP: 4.Managing Adverse Events in Novel Friedreich’s Ataxia Therapy
EP: 5.Examining Trial Data on Omaveloxolone Efficacy
EP: 6.Promising Therapy Approaches for Advanced Friedreich Ataxia
- What are some of the key recommendations outlined in the guidelines for managing FA published in November 2022?
- Could you elaborate on the significance of omaveloxolone as the first FDA-approved therapy for Friedreich’s ataxia and how you incorporate this treatment into your disease management regimen? Since the approval of omaveloxolone, what has been the impact on the management of advanced stages of the disease and life expectancy in FA patients?
Related Videos
Related Content
